FDA's expedited approval program is what the patient ordered

09/13/2012 | Forbes

Recent criticism that the FDA is sacrificing patient safety in a rush to approve drugs is unfounded, writes John L. LaMattina, former president of Pfizer Global Research and Development. Patients with life-threatening illnesses want access to promising medicines and are willing risk serious side effects, LaMattina writes. Moreover, the FDA attaches stringent requirements for risk evaluation and mitigation to expedited approval, he writes.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA